Skip to content

EBIT at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$46.53M-40.3%
Vor Biopharma logo
Vor BiopharmaVOR
-$35.16M-5.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.7M+2.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$39.05M+12.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's EBIT?
Annexon (ANNX) reported EBIT of -$46.05M in Q1 2026.
How has Annexon's EBIT changed year-over-year?
Annexon's EBIT increased by 19.8% year-over-year, from -$57.41M to -$46.05M.
What is the long-term trend for Annexon's EBIT?
Over 4 years (2021 to 2025), Annexon's EBIT has grown at a 13.4% compound annual growth rate (CAGR), from -$130.71M to -$216.41M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.